Clinical Trials Logo

IGA Glomerulonephritis clinical trials

View clinical trials related to IGA Glomerulonephritis.

Filter by:
  • None
  • Page 1

NCT ID: NCT02527902 Completed - Clinical trials for IGA Glomerulonephritis

Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy

Start date: January 2011
Phase: N/A
Study type: Interventional

The estimation of the cardiovascular risk in the general population must take into account small renal disturbances, as the microalbuminuria. Conversely certain parameters of the cardiovascular risk influence the evolution of renal diseases, for example the arterial high blood pressure. The measure of the activity of the autonomous nervous system, and especially the quantification of its variability, is a means to estimate the cardiovascular risk. The investigators formulate the hypothesis that the variability of the autonomous nervous system is an additional clinical element for the evaluation of the evolutionary risk of renal diseases. The aim of this study is to compare the variability of the autonomous nervous system during the various evolutionary stages of the renal disease. The renal disease studied will be IgA nephropathy (IgNA). IgNA is a histologically defined glomerulonephritis (rela biopsy) by the presence of deposits immunoglobulin A (IgA) in the renal mesangium (at list 1+) by immunofluorescence.

NCT ID: NCT01560052 Completed - Clinical trials for IgA Glomerulonephritis

Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)

TESTING
Start date: May 5, 2012
Phase: N/A
Study type: Interventional

This study will evaluate the long-term efficacy and safety of low dose oral methylprednisolone compared to matching placebo, on a background of routine RAS inhibitor therapy, in preventing kidney events in patients with IgA nephropathy and features suggesting a high risk of progression.

NCT ID: NCT01115426 Completed - Clinical trials for IGA Glomerulonephritis

Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis

Start date: January 1997
Phase: Phase 4
Study type: Interventional

This study evaluates prospectively the effects of an anti-angiotensin II regimen on renal outcome in patients with mesangioproliferative glomerulonephritis followed-up for 10 years.

NCT ID: NCT00006137 Completed - Clinical trials for IGA Glomerulonephritis

Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy

Start date: May 2000
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Determine the most sensitive outcome measures (functional or morphological) of a progressive renal injury in patients with IgA nephropathy. II. Determine which of these patients are destined to progress to further injury in order to target them for therapy. III. Elucidate the determinants of progression in those patients who exhibit evidence of either increasing impairment of ultrafiltration capacity or ongoing destruction of nephrons.

NCT ID: NCT00004448 Completed - Clinical trials for IGA Glomerulonephritis

Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy

Start date: November 1997
Phase: Phase 2
Study type: Interventional

OBJECTIVES: Evaluate the efficacy of alternate day prednisone versus daily fish oil supplements in slowing or preventing the decline in renal function in children, adolescents, and young adults with moderate to severe immunoglobulin A nephropathy.

NCT ID: NCT00004305 Completed - Clinical trials for IGA Glomerulonephritis

Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis

Start date: January 1998
Phase: N/A
Study type: Observational

OBJECTIVES: I. Determine whether allelic differences associated with the fourth component of complement, type-1 complement receptor expressed on erythrocytes, and Fc receptor FcgRIII contribute to the pathogenesis of IgA glomerulonephritis (IgA-N). II. Compare genetic anomalies of these key components in immune complex processing and clearance between juvenile vs adult onset IgA-N vs normal controls.